Konstantinos Segkos, MD
Endocrinology, Diabetes & Metabolism · Lehi, UTNPI 1700131844
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 176 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 17.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $783 and has fallen 64.9% since, to $275 in 2025. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in UT, where the typical reported total is $3,842.
Across 176 payments — averaging $17.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$544
- Amgen$503
- AstraZeneca$329
- Sanofi-aventis U.S. LLC$232
- Boehringer Ingelheim$163
- Pulse Biosciences, Inc.$128
- plus $1K from 28 others
What the payments were for
- Food & beverage$3,091100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 37 | $544 |
| Amgen(2 entities) | 23 | $503 |
| AstraZeneca(2 entities) | 15 | $329 |
| Sanofi-aventis U.S. LLC | 16 | $232 |
| Boehringer Ingelheim | 11 | $163 |
| Pulse Biosciences, Inc. | 1 | $128 |
| Johnson & Johnson | 7 | $123 |
| IBSA Pharma Inc. | 5 | $95 |
| Lilly USA, LLC | 6 | $93 |
| Bristol Myers Squibb | 4 | $86 |
| Vivus LLC | 4 | $68 |
| Shire North American Group Inc | 4 | $63 |
| Novo Nordisk | 4 | $58 |
| UCB, Inc. | 3 | $58 |
| Amneal Pharmaceuticals LLC | 4 | $54 |
| Ipsen Biopharmaceuticals, Inc | 3 | $49 |
| Neurocrine Biosciences, Inc. | 2 | $43 |
| Sobi, Inc | 3 | $43 |
| Currax Pharmaceuticals LLC | 3 | $41 |
| Nalpropion Pharmaceuticals LLC | 3 | $39 |
| Gilead | 2 | $36 |
| Corcept Therapeutics | 2 | $32 |
| Recordati_rare_diseases_inc. | 2 | $30 |
| GSK | 2 | $25 |
| Madrigal Pharmaceuticals | 1 | $21 |
| Ascendis Pharma Endocrinology Inc | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Radius Health, Inc. | 1 | $18 |
| ANI Pharmaceuticals, Inc. | 1 | $17 |
| Abbott | 1 | $17 |
| Actelion Pharmaceuticals US, Inc. | 1 | $16 |
| Pfizer | 1 | $15 |
| Amryt Pharma Holdings Ltd | 1 | $15 |
| Antares Pharma, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,103 in reported general payments places this provider in the 45th percentile of 38 endocrinology, diabetes & metabolism providers in Utah.
See all endocrinology, diabetes & metabolism providers in Utah →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levothyroxine Sodium | 224 | $2,791 |
| SynthroidLevothyroxine Sodium | 30 | $2,448 |
| Hydrocortisone | 12 | $279 |
| Methimazole | 23 | $160 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $54 | $2,791224 claims |
| AbbVieSynthroid | $544 | $2,44830 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 38 endocrinology, diabetes & metabolism providers in Utah.
Other endocrinology, diabetes & metabolism in Lehi
- Eliot BrintonSalt Lake City$733K
- Claudia FishPark City$286K
- Alireza Falahati-NiniSalt Lake City$241K
- Steven BrownLayton$105K
- Timothy GrahamSandy$90K
- Jack WahlenOgden$70K
- Mohammed NizamProvo$54K
- Shahzad AhmadSalt Lake City$25K
- Priya KrishnamurthySt George$22K
- Vishnu SundareshSalt Lake City$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.